Endocrine Dysfunction in P27Kip1 Deficient Mice and Susceptibility to Wnt-1 Driven Breast Cancer

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2009 Apr 22

PMID 19380520

Citations 5

Authors

Cynthia E Glover

Kay E Gurley

Kyung-Hoon Kim

Barry Storer

Mathew L Fero

Christopher J Kemp

Affiliations

Soon will be listed here.

Abstract

The cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) (p27) is a marker of prognosis in many cancers, including breast cancer. Low p27 expression correlates with poor prognosis, especially in hormone receptor positive breast tumors. This association suggests a role for p27 in hormone-dependent cancer. We used the Wnt-1 transgenic mouse model to further explore the role of p27 in hormone-driven breast cancer. We found that p27 deficiency did not alter breast cancer rate in either male or female Wnt-1 mice. However, we did find p27-/- females had reduced levels of serum progesterone (P) and increased variability in estradiol (E), which could have affected their cancer susceptibility. To equalize hormone levels, an additional cohort of Wnt-1 female mice was ovariectomized and implanted with slow release pellets of E and P. Although this treatment did not alter the breast cancer rate, it did accelerate the development of pituitary and gastric tumors in p27-/- mice. This study shows that while not a significant inhibitor of Wnt-1-driven breast cancer, p27 inhibits gastric tumors, whose latency is modulated by sex steroids.

Citing Articles

The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.

Grey W, Ivey A, Milne T, Haferlach T, Grimwade D, Uhlmann F Biochim Biophys Acta Mol Cell Res. 2017; 1865(1):105-116.

PMID: 28939057 PMC: 5701546. DOI: 10.1016/j.bbamcr.2017.09.009.

Genetic characterization of p27(kip1) and stathmin in controlling cell proliferation in vivo.

Berton S, Pellizzari I, Fabris L, DAndrea S, Segatto I, Canzonieri V Cell Cycle. 2014; 13(19):3100-11.

PMID: 25486569 PMC: 4612673. DOI: 10.4161/15384101.2014.949512.

An essential role of p27 downregulation in fenvalerate-induced cell growth in human uterine leiomyoma and smooth muscle cells.

Gao X, Yu L, Castro L, Tucker C, Moore A, Xiao H Am J Physiol Endocrinol Metab. 2012; 303(8):E1025-35.

PMID: 22850687 PMC: 3469610. DOI: 10.1152/ajpendo.00107.2012.

Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.

Markaverich B, Vijjeswarapu M, Shoulars K, Rodriguez M J Steroid Biochem Mol Biol. 2010; 122(4):219-31.

PMID: 20558290 PMC: 2949446. DOI: 10.1016/j.jsbmb.2010.06.006.

The function of p27 KIP1 during tumor development.

Lee J, Kim S Exp Mol Med. 2009; 41(11):765-71.

PMID: 19887899 PMC: 2788730. DOI: 10.3858/emm.2009.41.11.102.

References

Philipp-Staheli J, Kim K, Payne S, Gurley K, Liggitt D, Longton G . Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell. 2002; 1(4):355-68. DOI: 10.1016/s1535-6108(02)00054-5. View

Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K . p27 expression and gastric carcinoma. Nat Med. 1997; 3(6):593. DOI: 10.1038/nm0697-593. View

Myung N, Kim M, Chung I, Kim H, Jang J . Loss of p16 and p27 is associated with progression of human gastric cancer. Cancer Lett. 2000; 153(1-2):129-36. DOI: 10.1016/s0304-3835(00)00359-1. View

Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin D, Moser A . Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol. 2002; 161(3):1087-97. PMC: 1867237. DOI: 10.1016/S0002-9440(10)64269-1. View

Sherr C, Roberts J . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13(12):1501-12. DOI: 10.1101/gad.13.12.1501. View

Kawamata N, Morosetti R, Miller C, Park D, Spirin K, Nakamaki T . Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 1995; 55(11):2266-9. View

Fero M, Randel E, Gurley K, Roberts J, Kemp C . The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998; 396(6707):177-80. PMC: 5395202. DOI: 10.1038/24179. View

Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara E . Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res. 1997; 88(7):625-9. PMC: 5921483. DOI: 10.1111/j.1349-7006.1997.tb00428.x. View

Fero M, Rivkin M, Tasch M, Porter P, Carow C, Firpo E . A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996; 85(5):733-44. DOI: 10.1016/s0092-8674(00)81239-8. View

10.

Hwang H, Martins C, Bronkhorst Y, Randel E, Berns A, Fero M . Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc Natl Acad Sci U S A. 2002; 99(17):11293-8. PMC: 123250. DOI: 10.1073/pnas.162356099. View

11.

Kiyokawa H, Kineman R, Soares V, HOFFMAN E, Ono M, Khanam D . Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996; 85(5):721-32. DOI: 10.1016/s0092-8674(00)81238-6. View

12.

Min Y, Cheong J, Kim J, Eom J, Lee S, Hahn J . Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res. 2004; 64(15):5225-31. DOI: 10.1158/0008-5472.CAN-04-0174. View

13.

Tong W, Kiyokawa H, Soos T, Park M, Soares V, Manova K . The absence of p27Kip1, an inhibitor of G1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa->luteal transition. Cell Growth Differ. 1998; 9(9):787-94. View

14.

Cardiff R, Anver M, Gusterson B, Hennighausen L, Jensen R, Merino M . The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 2000; 19(8):968-88. DOI: 10.1038/sj.onc.1203277. View

15.

Spirin K, Simpson J, Takeuchi S, Kawamata N, Miller C, Koeffler H . p27/Kip1 mutation found in breast cancer. Cancer Res. 1996; 56(10):2400-4. View

16.

Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi P . Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet. 2001; 27(2):222-4. DOI: 10.1038/84879. View

17.

Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, HORII I . Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996; 85(5):707-20. DOI: 10.1016/s0092-8674(00)81237-4. View

18.

Pellegata N, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H . Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006; 103(42):15558-63. PMC: 1622862. DOI: 10.1073/pnas.0603877103. View

19.

Cariou S, Donovan J, Flanagan W, Milic A, Bhattacharya N, Slingerland J . Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A. 2000; 97(16):9042-6. PMC: 16818. DOI: 10.1073/pnas.160016897. View

20.

Li Y, Hively W, Varmus H . Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene. 2000; 19(8):1002-9. DOI: 10.1038/sj.onc.1203273. View